Lipocine Showcases LPCN 2101 for Epilepsy at 2025 AES Conference

Lipocine Advances Epilepsy Treatment at AES Conference

Lipocine Inc., a biopharmaceutical company specializing in innovative oral delivery solutions, showcases its commitment to addressing significant medical needs in the epilepsy treatment landscape. The company announces that two abstracts related to its epilepsy treatment candidate, LPCN 2101, receive acceptance for poster presentations at the upcoming 2025 American Epilepsy Society (AES) annual meeting in Atlanta, Georgia. This prestigious event, scheduled for December 5-9, 2025, provides a platform for Lipocine to present its research findings and engage with the broader medical community.

The first abstract, titled "Oral Toxicokinetics of a Bioidentical GABAA Receptor Modulating Neuroactive Steroid (NAS) Anti-seizure Medication (ASM) Candidate for Women with Epilepsy (WWE)," is set for presentation on December 7. This research focuses on the unique pharmacological properties of LPCN 2101, specifically its potential benefits for women, a demographic often underrepresented in epilepsy studies. The second abstract, presented on December 8, discusses the "Clinical Pharmacokinetics (PK) and Tolerability of a Novel Oral GABAA Receptor Positive Allosteric Modulating (PAM) Candidate for Epilepsy." Together, these presentations underscore Lipocine's dedication to developing treatments that offer new therapeutic avenues for patients suffering from epilepsy.

Lipocine's broader pipeline includes several promising drug candidates beyond LPCN 2101. Notable among these is LPCN 1154, an oral formulation of brexanolone aimed at treating postpartum depression, and LPCN 2203, targeted at managing essential tremors. The company also explores treatments for obesity and liver cirrhosis through LPCN 2401 and LPCN 1148, respectively. Additionally, Lipocine is actively seeking partnerships for LPCN 1107, a candidate designed to prevent preterm birth, indicating a strategic focus on diverse therapeutic areas. By advancing these innovative treatments, Lipocine aims to fulfill unmet medical needs across various patient populations, reinforcing its position in the biopharmaceutical industry.

In preparation for the AES meeting, the abstracts remain embargoed until November 24, 2025, a detail that highlights Lipocine's strategic approach to disseminating its research findings. The company's focus on patient-friendly oral delivery options positions it favorably within the biopharmaceutical sector, as it continues to explore novel therapies that offer both efficacy and convenience for patients.